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Conclusion:
In this real-world setting of AF patients receiving PCI, the risk of bleeding was lower in patients discharged on dual therapy and DAPT, with a trend for lower TEE, compared to triple therapy. This small study suggests acceptability of a clinical benefit of dual therapy in this scenario so that further investigation in larger studies is warranted. Background: Dobutamine stress echocardiography (DSE) is a commonly used diagnostic stress test for the assessment of various cardiac pathologies on patients unable to perform exercise. Unlike exercise, there is no reliable subjective termination end-point such as fatigue to rely on. Consequently, DSEs are often concluded at a predetermined age predicted maximal heart rate (APMHR) such as 85%, however the validity of this practice is undefined. The aim of this study was to assess if the maximum rate pressure product (MRPP) and APMHR are valid measures of future cardiovascular (CV) events during DSE.
Methods: Following exclusions, receiver operating curve (ROC) analyses were performed on 740 patients for MRPP and APMHR, using CV events during the follow-up period (3.7 ± 1.7 years) as the outcome variable.
Results: ROC analyses failed to produce a statistically valid model for MRPP (p = 0.130, area under curve (AUC) = 0.556) with a sensitivity and specificity of 24.8% and 90.2% respectively at the optimal cut point (15147 MRPP). To the contrary, analyses of APMHR demonstrated a heart rate percentage of 89.3 to be a useful predictor of future CV events with a sensitivity and specificity of 70.3% and 60.1% respectively (p < 0.0001, AUC 0.680).
Conclusion: The current study demonstrates MRPP as a poor measure of CV event prediction during DSE. However, an APMHR of 89.3% demonstrated a statistically valid model, suggesting a better termination end-point than the previously unverified 85% APMHR during DSE where subjective measures such as fatigue do not apply. 
